Contact:  Christophe Demaison, CEO
Website:   www.innavac.com

Innavac Pty Ltd is a biotechnology company spun out of the University of Melbourne that is developing novel, synthetic Toll-like receptor (TLR) agonists as vaccine adjuvants and for the prevention and treatment of respiratory infections.  It is based on research by Professor David Jackson and his team at the Department of Immunology / Peter Doherty Institute for Infection and Immunity, and also by Dr Nathan Bartlett, a world expert on in vivo models of respiratory viral infections based at the Hunter Medical Research Institute.  Early studies indicate that Innavac’s TLR agonists are broad-spectrum agents that leverage the innate immune system to prevent respiratory tract viral infections such as cold, flu, Respiratory syncytial Virus (RSV) and bacterial infections.